vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and CAPITAL CITY BANK GROUP INC (CCBG). Click either name above to swap in a different company.

CAPITAL CITY BANK GROUP INC is the larger business by last-quarter revenue ($63.5M vs $44.9M, roughly 1.4× AbCellera Biologics Inc.). CAPITAL CITY BANK GROUP INC runs the higher net margin — 21.6% vs -19.9%, a 41.5% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 6.0%). CAPITAL CITY BANK GROUP INC produced more free cash flow last quarter ($80.0M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 6.0%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.

ABCL vs CCBG — Head-to-Head

Bigger by revenue
CCBG
CCBG
1.4× larger
CCBG
$63.5M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+782.4% gap
ABCL
788.4%
6.0%
CCBG
Higher net margin
CCBG
CCBG
41.5% more per $
CCBG
21.6%
-19.9%
ABCL
More free cash flow
CCBG
CCBG
$124.6M more FCF
CCBG
$80.0M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
6.0%
CCBG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
CCBG
CCBG
Revenue
$44.9M
$63.5M
Net Profit
$-8.9M
$13.7M
Gross Margin
Operating Margin
-63.7%
29.3%
Net Margin
-19.9%
21.6%
Revenue YoY
788.4%
6.0%
Net Profit YoY
73.9%
4.7%
EPS (diluted)
$-0.03
$0.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
CCBG
CCBG
Q4 25
$44.9M
$63.5M
Q3 25
$9.0M
$65.9M
Q2 25
$17.1M
$63.2M
Q1 25
$4.2M
$61.5M
Q4 24
$5.0M
$59.9M
Q3 24
$6.5M
$59.7M
Q2 24
$7.3M
$58.9M
Q1 24
$10.0M
$56.5M
Net Profit
ABCL
ABCL
CCBG
CCBG
Q4 25
$-8.9M
$13.7M
Q3 25
$-57.1M
$15.9M
Q2 25
$-34.7M
$15.0M
Q1 25
$-45.6M
$16.9M
Q4 24
$13.1M
Q3 24
$-51.1M
$13.1M
Q2 24
$-36.9M
$14.2M
Q1 24
$-40.6M
$12.6M
Operating Margin
ABCL
ABCL
CCBG
CCBG
Q4 25
-63.7%
29.3%
Q3 25
-851.8%
32.0%
Q2 25
-290.2%
31.7%
Q1 25
-1479.6%
35.8%
Q4 24
29.0%
Q3 24
-1439.4%
26.1%
Q2 24
-1276.2%
29.3%
Q1 24
-551.5%
27.2%
Net Margin
ABCL
ABCL
CCBG
CCBG
Q4 25
-19.9%
21.6%
Q3 25
-637.8%
24.2%
Q2 25
-203.3%
23.8%
Q1 25
-1077.2%
27.4%
Q4 24
21.9%
Q3 24
-785.4%
22.0%
Q2 24
-504.3%
24.0%
Q1 24
-408.0%
22.2%
EPS (diluted)
ABCL
ABCL
CCBG
CCBG
Q4 25
$-0.03
$0.80
Q3 25
$-0.19
$0.93
Q2 25
$-0.12
$0.88
Q1 25
$-0.15
$0.99
Q4 24
$0.78
Q3 24
$-0.17
$0.77
Q2 24
$-0.13
$0.83
Q1 24
$-0.14
$0.74

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
CCBG
CCBG
Cash + ST InvestmentsLiquidity on hand
$128.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$552.9M
Total Assets
$1.4B
$4.4B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
CCBG
CCBG
Q4 25
$128.5M
Q3 25
$83.2M
Q2 25
$92.4M
Q1 25
$159.3M
Q4 24
$156.3M
Q3 24
$126.6M
Q2 24
$148.3M
Q1 24
$123.6M
Stockholders' Equity
ABCL
ABCL
CCBG
CCBG
Q4 25
$966.9M
$552.9M
Q3 25
$964.0M
$540.6M
Q2 25
$1.0B
$526.4M
Q1 25
$1.0B
$512.6M
Q4 24
$1.1B
$495.3M
Q3 24
$1.1B
$476.5M
Q2 24
$1.1B
$461.0M
Q1 24
$1.1B
$448.3M
Total Assets
ABCL
ABCL
CCBG
CCBG
Q4 25
$1.4B
$4.4B
Q3 25
$1.4B
$4.3B
Q2 25
$1.4B
$4.4B
Q1 25
$1.3B
$4.5B
Q4 24
$1.4B
$4.3B
Q3 24
$1.4B
$4.2B
Q2 24
$1.4B
$4.2B
Q1 24
$1.5B
$4.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
CCBG
CCBG
Operating Cash FlowLast quarter
$-34.7M
$87.6M
Free Cash FlowOCF − Capex
$-44.6M
$80.0M
FCF MarginFCF / Revenue
-99.4%
126.1%
Capex IntensityCapex / Revenue
21.9%
12.0%
Cash ConversionOCF / Net Profit
6.39×
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$150.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
CCBG
CCBG
Q4 25
$-34.7M
$87.6M
Q3 25
$-52.6M
$21.6M
Q2 25
$-32.4M
$32.6M
Q1 25
$-11.6M
$21.9M
Q4 24
$-108.6M
$63.6M
Q3 24
$-28.9M
$12.8M
Q2 24
$-30.0M
$24.9M
Q1 24
$-41.7M
$14.6M
Free Cash Flow
ABCL
ABCL
CCBG
CCBG
Q4 25
$-44.6M
$80.0M
Q3 25
$-61.5M
$19.8M
Q2 25
$-45.8M
$30.8M
Q1 25
$-22.2M
$19.5M
Q4 24
$-187.0M
$54.9M
Q3 24
$-47.4M
$10.5M
Q2 24
$-50.1M
$23.0M
Q1 24
$-65.8M
$12.4M
FCF Margin
ABCL
ABCL
CCBG
CCBG
Q4 25
-99.4%
126.1%
Q3 25
-687.0%
30.1%
Q2 25
-267.9%
48.7%
Q1 25
-524.0%
31.7%
Q4 24
-3702.8%
91.7%
Q3 24
-728.4%
17.6%
Q2 24
-683.8%
39.0%
Q1 24
-661.5%
22.0%
Capex Intensity
ABCL
ABCL
CCBG
CCBG
Q4 25
21.9%
12.0%
Q3 25
99.7%
2.6%
Q2 25
78.2%
2.9%
Q1 25
251.1%
3.9%
Q4 24
1552.7%
14.5%
Q3 24
284.6%
3.8%
Q2 24
274.6%
3.3%
Q1 24
242.5%
4.0%
Cash Conversion
ABCL
ABCL
CCBG
CCBG
Q4 25
6.39×
Q3 25
1.35×
Q2 25
2.17×
Q1 25
1.30×
Q4 24
4.86×
Q3 24
0.97×
Q2 24
1.76×
Q1 24
1.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons